Skip to content
Screener

AnaptysBio, Inc. ANAB External Expenses — General And Administrative Expense

Other product segments

Internal Expenses
$14.08M+63.9%

Similar metrics at other companies

TRA
TRAXExternal Expenses — General And Administrative Expense
$8.72M+127%
Beam Therapeutics logo
BEAMExternal General And Administrative Expenses — General And Administrative Expense
$13.37M+149%
Solid Biosciences Inc. logo
SLDBExternal General And Administrative Expense — General And Administrative Expense
$6.33M+19.9%
Solid Biosciences Inc. logo
SLDBInternal General And Administrative Expense — General And Administrative Expense
$4.73M+40.9%
TRA
TRAXInternal Expense — General And Administrative Expense
$10.14M+69.9%
Rein Therapeutics Inc. logo
RNTXEmployee Related Expenses — General And Administrative Expense
$859K-9.3%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.62B+145%
Enterprise value$1.37B+117%
P/S+1.6×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515
Line itemBiopharmaRoyalty ManagementTotal
Total External R&D(1)18,6422118,663
Total Internal R&D(2)15,3131515,328
Total R&D33,9553633,991
External G&A(3)8,7213,39812,119
Internal G&A(2)10,1353,94814,083
Total G&A18,8567,34626,202
Total operating expenses52,8117,38260,193
(Loss) income from operations(52,811)18,174(34,637)

Item 1. Consolidated Financial Statements

FAQ

What is AnaptysBio, Inc.'s external expenses — general and administrative expense?
AnaptysBio, Inc. (ANAB) reported external expenses — general and administrative expense of $12.12M in Q1 2026.
How has AnaptysBio, Inc.'s external expenses — general and administrative expense changed year-over-year?
AnaptysBio, Inc.'s external expenses — general and administrative expense increased by 118.8% year-over-year, from $5.54M to $12.12M.
What is the long-term trend for AnaptysBio, Inc.'s external expenses — general and administrative expense?
Over 3 years (2022 to 2025), AnaptysBio, Inc.'s external expenses — general and administrative expense has grown at a 35.1% compound annual growth rate (CAGR), from $7.29M to $17.94M.
What does external expenses — general and administrative expense mean?
This metric captures the overhead and operational costs associated with supporting the administrative functions of a specific business segment. It includes expenses such as executive management, legal, human resources, and general office support that are not directly tied to research activities. Tracking this helps assess the scalability and cost-efficiency of the company's operational infrastructure.

Ask your AI about AnaptysBio, Inc.'s external expenses — general and administrative expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude